Last reviewed · How we verify

Vibativ — Competitive Intelligence Brief

Vibativ (TELAVANCIN) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lipoglycopeptide Antibacterial. Area: Metabolic.

marketed Lipoglycopeptide Antibacterial Metabolic Recombinant protein Live · refreshed every 30 min

Target snapshot

Vibativ (TELAVANCIN) — Cumberland. Vibativ works by binding to the bacterial cell wall, disrupting its synthesis and ultimately leading to cell death.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Vibativ TARGET TELAVANCIN Cumberland marketed Lipoglycopeptide Antibacterial 2009-01-01
Dalvance DALBAVANCIN AbbVie marketed Lipoglycopeptide Antibacterial 2014-01-01
Orbactiv ORITAVANCIN Melinta Therap marketed Lipoglycopeptide Antibacterial 2014-01-01
Vibativ TELAVANCIN HYDROCHLORIDE Cumberland marketed Lipoglycopeptide Antibacterial 2009-01-01

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lipoglycopeptide Antibacterial class)

  1. Cumberland · 2 drugs in this class
  2. AbbVie · 1 drug in this class
  3. Melinta Therap · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vibativ — Competitive Intelligence Brief. https://druglandscape.com/ci/telavancin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: